Anti-Obesity Pill Wins Approval

Source: Associated Press (7/17/12)

"Vivus Inc.'s Qsymia is the second weight-loss drug approved by the FDA in less than a month, following Arena Pharmaceutical's pill Belviq in late June."

Associated Press

A new weight-loss pill that many doctors consider the most effective of a new generation of anti-obesity drugs got the approval of the U.S. Food and Drug Administration on Tuesday.

The pill, called Qsymia, was approved for patients who are overweight or obese and also have at least one weight-related condition such as high blood pressure, diabetes or high cholesterol.

The drug offers hope for those who have failed to lose weight in other ways, but its path to approval also underscores how difficult it has been for drugmakers to find obesity treatments that are safe and effective.

The drug's maker, Vivus Inc., said it plans to bring the drug to market in the fourth quarter of this year. It hasn't yet decided what the pills will cost. . .View Full Article

Report of FDA Drug Approval Delay is 'Likely Noise': Analyst
Source: Douglas Tsao (01/27/2026)

Disc Medicine Inc.'s (IRON:NASDAQ) chances of bitopertin getting approved remain unaltered by the claims in a recent article, noted an H.C. Wainwright & Co. report. Read on to learn the reasons behind this opinion of the investment bank.

AI Collaboration Expands to Accelerate Cancer Drug Discovery
Source: Streetwise Reports (01/12/2026)

Rakovina Therapeutics Inc. (RKV:TSX.V) has broadened its partnership with Variational AI to refine next-generation ATR inhibitors using generative AI. The agreement aims to streamline lead optimization for the company's kt-5000 series of small-molecule cancer drug candidates.

Analysts Highlight Notable H1/26 Catalysts in Biotech
Source: RBC Capital Markets (01/12/2026)

Despite the overall run-up in biotech names last year, the sector still offers "several attractive H1/26 catalyst set-ups, noted an RBC Capital Markets report. Find out which upcoming events the analysts like the most and the least.

Expanded AI Collaboration Advances Optimization of Cancer Drug Candidates
Source: Streetwise Reports (01/09/2026)

Rakovina Therapeutics Inc. (RKV:TSX.V) has expanded its partnership with Variational AI to advance optimization of its kt-5000 ATR inhibitor series. Learn how the agreement deepens the company's use of generative AI to refine small-molecule drug candidates and accelerate preclinical selection.

Clean-Tech Co. Looks Forward to Massive Market Breakthroughs in 2026
Source: Streetwise Reports (12/31/2025)

BioLargo Inc.'s (BLGO:OTCQX) President and Chief Executive Officer Dennis P. Calvert notes the company is looking forward to its part in "what may be one of the largest infrastructure and technology investment cycles in history."